神经精神药物的药物基因组学检测临床应用

Clinical Application of Pharmacogenomic Testing for Neuropsychiatric Drugs

近年来,药物基因组学检测逐渐从实验室研究走向临床实践,为个体化给药方案的制定提供了一种新的检测手段。其中,神经精神科药物的药物基因组学检测技术的临床应用取得一定成果,根据现有的遗传学信息对三环类抗抑郁药卡马西平、苯妥英等神经精神药物进行药物选择和(或)剂量调整已经被美国食品药品监督管理局(FDA)的说明书及相关的指南共识采纳,以帮助临床医生使用药物基因组学检测技术调整用药。本综述药物基因组学检测在神经精神药物中的临床应用、神经精神药物的药物基因组学检测的发展、相关指南共识、FDA说明书中各类神经精神科药物的基因检测的研究进展,为临床医生应用该项技术提供参考。

Pharmacogenomic testing has turned research into clinical practice in recent years, which provides a new technology for personalized medicine. Currently, some advances in pharmacogenomics for neuropsychiatric drugs have been made as FDA labeling and guidelines exists to assist clinicians in the use of existing genetic information for drug selection and/or dosing for tricyclic antidepressants, carbamazepine, and phenytoin. In order to help clinicians understand and apply the technology, it were outlined that the clinical application of pharmacogenomic testing for neuropsychiatric drugs by summarizing the development of pharmacogenomic testing for neuropsychiatric drugs as well as relevant information contained in FDA drug labeling and guidelines.